Question 1

What is DATOPOTAMAB DERUXTECAN used for?

Accepted Answer

DATOPOTAMAB DERUXTECAN (brand name DATROWAY) is a Other indicated for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, HR-Positive.

Question 2

How does DATOPOTAMAB DERUXTECAN work?

Accepted Answer

DATOPOTAMAB DERUXTECAN works through the following mechanism: 12.1 Mechanism of Action Datopotamab deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to Trop-2 on cells, including tumor cells, datopotamab deruxtecan-dlnk undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death. Datopotamab deruxtecan-dlnk had anti-tumor activity in mouse models of lung cancer including EGFR-mutated and breast cancer..

Question 3

What are the most common side effects of DATOPOTAMAB DERUXTECAN?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for DATOPOTAMAB DERUXTECAN. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is DATOPOTAMAB DERUXTECAN the same as DATROWAY?

Accepted Answer

DATROWAY is a brand name for DATOPOTAMAB DERUXTECAN. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

DATOPOTAMAB DERUXTECAN

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations